Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories has launched Desloratadine Orally Disintegrating Tablets (ODT) (2.5 mg & 5 mg), a bioequivalent generic version of Clarinex Reditabs (desloratadine) in the US market on January 24, 2013. Dr Reddy’s ANDA for Desloratadine ODT is approved by the United States Food & Drug Administration (USFDA). The company’s Desloratadine ODT 2.5 mg & 5 mg are available in unit dose packages of 30 (5x6).

The Clarinex Reditabs brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.